Drug and alcohol dependence reports最新文献

{"title":"Real-world effectiveness of Motivational Enhancement for Engagement in Treatment (MEET) to improve substance use disorder care transitions","authors":"Brent R. Crandal ,&nbsp;William H. Eger ,&nbsp;Naomi Hillery ,&nbsp;Amy Panczakiewicz ,&nbsp;Zhun Xu ,&nbsp;Freddy Arriola ,&nbsp;Kelsey S. Dickson","doi":"10.1016/j.dadr.2025.100332","DOIUrl":"10.1016/j.dadr.2025.100332","url":null,"abstract":"<div><h3>Introduction</h3><div>Substance use disorder (SUD) treatment effectiveness relies on service continuity during care transitions (e.g., residential to outpatient). Motivational Enhancement for Engagement in Treatment (MEET) is a structured engagement-focused intervention designed to improve service utilization. This study tests the real-world effectiveness of MEET for individuals transitioning between SUD treatment settings.</div></div><div><h3>Methods</h3><div>Individuals receiving withdrawal management and residential SUD treatment in the San Diego County Behavioral Health Services Drug Medi-Cal Organized Delivery System between March 2021–January 2022 were included in this study. We used logistic regression via generalized estimating equations to calculate adjusted odds ratios (AORs) and 95 % confidence intervals (CIs) that accounted for clustering within treatment facilities and individuals, and stabilized inverse probability of treatment weighting (IPTW) of baseline covariates to assess the probability of connecting to step-down SUD treatment given intervention status (MEET or treatment as usual). We also assessed the probability of timely connection to step-down treatment (i.e., within 10 days of discharge).</div></div><div><h3>Results</h3><div>Of 10,011 participants in this quasi-experimental study, 141 (1.4 %) received MEET. Participants who received MEET were more likely to be connected to SUD treatment (AOR=1.79, 95 % CI: 1.11, 2.90) and of being connected in ≤ 10 days (AOR=1.65, 95 % CI: 1.01, 2.70) than participants who did not receive the intervention.</div></div><div><h3>Conclusions</h3><div>Among individuals with a SUD, MEET demonstrated real-world effectiveness for improving connections to step-down care, with participants receiving the intervention having nearly twice the odds of timely connection. This indicates practical engagement-based interventions can improve SUD treatment continuity across care transitions.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100332"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social media for recovery support for people with substance use disorder. A cross-sectional study of use patterns and motivations","authors":"Chanda Phelan ,&nbsp;Abby P.M. Katz ,&nbsp;Jennifer E. Merrill ,&nbsp;Kristina M. Jackson ,&nbsp;Tyler B. Wray","doi":"10.1016/j.dadr.2025.100331","DOIUrl":"10.1016/j.dadr.2025.100331","url":null,"abstract":"<div><h3>Objective</h3><div>This study examined the use of social media for recovery support among individuals with substance use disorder (SUD) with past-year treatment attendance and tested whether demographic and SUD history factors were associated with use of social media for recovery support.</div></div><div><h3>Method</h3><div>Participants (N = 255; 45 % female, 85 % white, mean age = 41.4 [9.6]) recently treated for SUD completed an online survey. The survey gathered demographics, SUD histories, and social media use data. We report descriptive statistics and logistic regression models testing relationships between social media for recovery support and individual factors.</div></div><div><h3>Results</h3><div>Forty percent of participants used social media for recovery support, and most believed it beneficial. Being female increased use likelihood (OR = 2.56, 95 % CI [1.49, 4.46]), while older age (50 +) was associated with lower use likelihood than young adults (18−35) (OR = 0.35, 95 % CI [0.14, 0.84]). Social media was used primarily to build support systems and follow recovery-related content. Most found support forums on their own, and engaged with the groups for meaningful amounts of time (<u>&gt;</u>weekly, <u>&gt;</u>15<!--> <!-->minutes).</div></div><div><h3>Conclusions</h3><div>Results highlight how common it is to use social media for recovery support. Given the sparse evidence on its efficacy, more research is urgently needed to establish whether recovery support forums on social media convey actual benefits, and how to shape one’s digital environment to maximize those benefits.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100331"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of recent stimulant use on treatment outcomes amongst individuals initiating medications for opioid use disorders: Secondary analysis of a multisite randomized controlled trial","authors":"Cari Coles ,&nbsp;Courtney Batts ,&nbsp;Joanne Bae ,&nbsp;Gabriela León ,&nbsp;Alex Schmidt ,&nbsp;Sterling M. McPherson ,&nbsp;Crystal L. Smith ,&nbsp;André C. Miguel","doi":"10.1016/j.dadr.2025.100330","DOIUrl":"10.1016/j.dadr.2025.100330","url":null,"abstract":"<div><h3>Introduction</h3><div>Illicit stimulant use among individuals initiating medication for opioid use disorder (MOUD) has significantly increased over the past decade. Co-use of these substances is associated with increased risk of mortality as well as worse treatment outcomes. This study examines the potential predictive role of stimulant urinalysis result at baseline on treatment retention and opioid and stimulant use outcomes amongst individuals initiating MOUD treatment.</div></div><div><h3>Methods</h3><div>This is a cross-sectional secondary analysis of data from a multi-site randomized clinical trial (CTN-0027). A total of 1269 individuals were randomized to receive 24 weeks of buprenorphine (n = 740) or methadone (n = 529) treatment across nine sites. Multiple linear and logistic regressions were conducted to determine the impact of baseline stimulant urinalysis results on treatment retention, and stimulant and opioid use outcomes.</div></div><div><h3>Results</h3><div>Individuals initiating MOUD with a stimulant negative urinalysis result at baseline submitted more negative stimulant (ꞵ=7.8; 95 % CI 6.8–8.7) and opioid (ꞵ=2.8; 95 % CI 1.8–3.8) urinalyses during treatment, were more likely to complete treatment (aOR=1.4; 95 % CI 1.1–1.7), and had better outcomes at six-month follow-up, measured as negative urinalysis for stimulant (aOR=5.3; 95 % CI 3.6–7.7), and opioid (aOR=1.8; 95 % CI 1.3–2.6).</div></div><div><h3>Conclusion</h3><div>Baseline stimulant use is associated with worse MOUD treatment outcomes, underscoring the need for novel integrated interventions designed to address opioid and stimulant co-use.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100330"},"PeriodicalIF":0.0,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series","authors":"Victoria Hayes ,&nbsp;Llewellyn Mills ,&nbsp;Gaye Byron ,&nbsp;Carolyn Stubley ,&nbsp;Eleanor Black ,&nbsp;Benjamin T. Trevitt ,&nbsp;Andrew A. Somogyi ,&nbsp;Arshman Sahid ,&nbsp;Nicholas Lintzeris","doi":"10.1016/j.dadr.2025.100329","DOIUrl":"10.1016/j.dadr.2025.100329","url":null,"abstract":"<div><h3>Introduction</h3><div>Long-acting injectable buprenorphine (LAIB) products are being increasingly used to treat patients with opioid dependence. Limited data is available on the severity or timespan (time to onset, peak, duration) of withdrawal signs and symptoms following discontinuation of treatment.</div></div><div><h3>Methods</h3><div>Participants aiming to discontinue long-term LAIB treatment commenced the study on the day of their final dose of Buvidal® 64<!--> <!-->mg Monthly. Participants were monitored with weekly assessments of withdrawal severity, cravings, general health, and patient experience measures for up to 16 weeks after last dose.</div></div><div><h3>Results</h3><div>Fifteen participants – those who remained for at least four weeks after the last LAIB dose – were included in the study. There was minimal increase in withdrawal severity over the study period, with an average peak Clinical Opioid Withdrawal Scale score of 4.8 ± 2.7, occurring at a median of 6 weeks (IQR 4–7.5) after the last LAIB dose. Cravings scores were generally low but increased gradually over the 16-week study period. There was no deterioration in physical or mental health scores, and participants reported high levels of satisfaction with the withdrawal experience. Ten participants used rescue medications, predominately in weeks 5 or 6 after the last dose.</div></div><div><h3>Discussion and conclusions</h3><div>Participants (last dose of Buvidal® 64<!--> <!-->mg Monthly) experienced minimal or mild withdrawal signs and symptoms, usually peaking in severity between 5 and 8 weeks after the last dose. These results are encouraging, however clinical trials comparing withdrawal outcomes between LAIB, sublingual buprenorphine (SL BPN) and methadone are required to inform treatment planning.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100329"},"PeriodicalIF":0.0,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders","authors":"Rebecca Fish ,&nbsp;Céu Mateus ,&nbsp;Hannah Maiden ,&nbsp;Euan Lawson ,&nbsp;Mark Limmer","doi":"10.1016/j.dadr.2025.100328","DOIUrl":"10.1016/j.dadr.2025.100328","url":null,"abstract":"<div><h3>Introduction</h3><div>Long-acting injectable buprenorphine (LAIB) is a relatively novel pharmacological treatment for people with opioid dependence. Despite growing qualitative evidence, there is limited research on practitioner insights, and effectiveness of LAIB in a community setting.</div></div><div><h3>Methods</h3><div>Thirteen service-users (11 currently prescribed LAIB), 6 practitioners, and 4 stakeholders (public health workers) took part in semi-structured interviews (n = 23) to glean their perspectives on LAIB. They were recruited through a community drug treatment service in the NW of England. The interview schedule was informed by previous literature and co-produced with a peer worker with lived experience of drug recovery treatment. Transcripts were analysed thematically by the research team.</div></div><div><h3>Results</h3><div>Four major themes were identified from the interviews: A change of focus; challenges; wrap-around support; and target groups.</div></div><div><h3>Discussion</h3><div>Our findings support existing evidence around the individual benefits to service-users such as changes to lifestyle and reduction of stigma, as well as challenges such as the need for wrap-around support and accessible information. We found that commissioning considerations such as geographical inequalities and the need for multi-service collaboration are important in this setting.</div></div><div><h3>Conclusions</h3><div>LAIB treatment works well for many people in a community context that offers significant wrap-around support to service-users. The novelty of this research lies in bringing together the views of practitioners and stakeholders as well as treatment/service beneficiaries in evaluating the introduction of LAIB in a community service.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100328"},"PeriodicalIF":0.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naloxone training programs in corporately-owned versus independently-owned Alabama community pharmacies: A pilot cross-sectional survey","authors":"Erin Blythe ,&nbsp;Nicholas McCormick ,&nbsp;Shannon Woods ,&nbsp;Karen Pham ,&nbsp;Asia White ,&nbsp;Hannah Bricker ,&nbsp;Sadie Newhouse ,&nbsp;Anne Taylor ,&nbsp;Lindsey Hohmann","doi":"10.1016/j.dadr.2025.100326","DOIUrl":"10.1016/j.dadr.2025.100326","url":null,"abstract":"<div><h3>Introduction</h3><div>Alabama community pharmacists have the ability to furnish naloxone. The purpose of this study was to identify the differences between naloxone training, policies, procedures, and preferences in corporately-owned (chain) versus independently-owned pharmacies in Alabama.</div></div><div><h3>Methods</h3><div>An online cross-sectional survey was distributed to Alabama community pharmacists via email. Outcome measures included: 1) in-house versus outsourced naloxone education/training topics (13-item multiple-choice); 2) naloxone training preferences (5-item multiple-choice); and 3) perceived usefulness of naloxone education sources (14-item Likert scale from 1 =strongly disagree to 5 =strongly agree). Data were analyzed using descriptive statistics, 2-sided Fisher’s Exact tests for categorical and Mann Whitney U tests for continuous/ordinal outcomes.</div></div><div><h3>Results</h3><div>Among the respondents (N = 64), 37 % were female, 95 % White, with an average age of 42 years. Less pharmacists received naloxone training (77 % vs 98 %, p = 0.016), naloxone education mandated by employers (7 % vs 97 %, p &lt; 0.001), and mean[SD] in-house naloxone education topics (3.7[4.9] vs 8.5[4.2], p = 0.003) in independent versus chain pharmacies. Most independent and chain pharmacies preferred naloxone training in an online self-study format (53 % vs 45 %, p = 0.529). However, mean[SD] perceived usefulness of training sources was lower for employer-based training (2.93[0.96] vs 3.90[1.01], p = 0.003), the Alabama Department of Public Health (2.87[1.19] vs 3.66[0.90], p = 0.024), and the Veterans Affairs Administration (1.60[0.91] vs 2.41[0.98], p = 0.013) amongst independents versus chains.</div></div><div><h3>Conclusions</h3><div>Findings suggest that pharmacists are not all receiving the same training in independent versus chain pharmacies. Targeted training efforts, including development of educational programs tailored to preferences in pharmacy settings, may lead to more efficient and informed provision of naloxone.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100326"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase I pilot study of a mobile education tool for supporting pregnant women with opioid use disorder","authors":"Ekaterina Burduli ,&nbsp;Jessica Fitts Willoughby ,&nbsp;Kaylee Paulsgrove ,&nbsp;Anna Winquist ,&nbsp;Sterling M. McPherson ,&nbsp;Ron Kim Johnson ,&nbsp;Hendrée E. Jones","doi":"10.1016/j.dadr.2025.100327","DOIUrl":"10.1016/j.dadr.2025.100327","url":null,"abstract":"<div><h3>Background</h3><div>Perinatal opioid use disorder (OUD) and neonatal abstinence syndrome (NAS) require targeted interventions to address gaps in maternal education and support. Maternal involvement in non-pharmacological NAS care is essential for improving neonatal outcomes, yet many mothers lack accessible resources to manage NAS symptoms and to navigate social and healthcare challenges. Mobile health applications offer a promising solution, but few cater specifically to the needs of perinatal women with OUD.</div></div><div><h3>Objective</h3><div>We assessed the usability, acceptability, and feasibility of a new mobile educational tool for pregnant women with OUD, focusing on the perinatal period and NAS care.</div></div><div><h3>Results</h3><div>Six perinatal women with OUD (n = 1 pregnant, n = 5 postpartum; mean age 31) found the tool highly acceptable (modified CSQ-8 mean=28.8 out of 32) and usable (modified SUS mean=45.0 out of 50). Most were likely to use the tool during pregnancy and postpartum, citing improved preparedness for advocating for themselves, managing NAS, and navigating CPS. Feedback suggested expanding content on infant withdrawal medications.</div></div><div><h3>Conclusions</h3><div>This mobile tool shows promise in empowering perinatal women with OUD. Further research is needed to evaluate its impact on clinical and neonatal outcomes.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100327"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of SSRI and SNRI co-prescription on benzodiazepine prescription trajectories","authors":"Kerry L. Kinney ,&nbsp;Eliseu da Cruz Moreira-Junior ,&nbsp;Laís F. Berro ,&nbsp;Matthew C. Morris ,&nbsp;James K. Rowlett","doi":"10.1016/j.dadr.2025.100325","DOIUrl":"10.1016/j.dadr.2025.100325","url":null,"abstract":"<div><h3>Purpose</h3><div>This study examined whether co-prescription of selective serotonin reuptake inhibitors (SSRIs) or serotonin or norepinephrine reuptake inhibitors (SNRI)s with benzodiazepines is associated with differences in benzodiazepine prescriptions both within individual patients over time and between patients.</div></div><div><h3>Methods</h3><div>We analyzed deidentified electronic health records of patients prescribed a benzodiazepine between 2020 and 2022 (<em>N</em> = 847). Patients were categorized into three groups: those co-prescribed an SSRI, those co-prescribed an SNRI, and those not co-prescribed an SSRI or SNRI.</div></div><div><h3>Results</h3><div>Individuals co-prescribed an SSRI (<em>M</em>=6.63) or an SNRI (<em>M</em>=8.31) had more benzodiazepine prescription encounters than those who were not co-prescribed an SSRI/SNRI (<em>M</em>=5.08). Individuals co-prescribed an SSRI or SNRI also received a higher maximum benzodiazepine dosage than those who were not co-prescribed an SSRI/SNRI (SSRI <em>M</em>=2.41; SNRI <em>M</em>=2.30; No SSRI/SNRI <em>M</em>=1.91 diazepam milligram equivalent defined daily doses). Multilevel models indicated the SSRI co-prescription group received a higher initial benzodiazepine dosage (<em>b</em>=0.394), but showed no significant change in benzodiazepine dosage over time. When controlling for demographic and clinical correlates of benzodiazepine prescriptions, those who were not co-prescribed an SSRI showed an increase in benzodiazepine dose over time (<em>b</em>=0.075). Multilevel models revealed no relationship between SNRI co-prescription and starting benzodiazepine dosage or change in benzodiazepine dosage over time. An anxiety disorder diagnosis, younger age, and non-Black/African American race were associated with higher benzodiazepine dose.</div></div><div><h3>Conclusions</h3><div>Individuals who are co-prescribed an SSRI/SNRI may be vulnerable to longer treatment durations and higher prescribed doses of benzodiazepines, raising concerns about risk for dependence among individuals receiving combined benzodiazepine and SSRI/SNRI treatment.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100325"},"PeriodicalIF":0.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The psychostimulant drug, fenethylline (captagon): Health risks, addiction and the global impact of illicit trade","authors":"Matthew Chidozie Ogwu ,&nbsp;Matěj Malík ,&nbsp;Pavel Tlustoš ,&nbsp;Jiří Patočka","doi":"10.1016/j.dadr.2025.100323","DOIUrl":"10.1016/j.dadr.2025.100323","url":null,"abstract":"<div><div>Fenethylline (street name, captagon) is a synthetic amphetamine-type stimulant that is emerging as a significant public health and security concern, particularly in the Middle East. This systematic review synthesizes original research articles, epidemiological studies, systematic reviews, policy analyses, and case reports to provide a comprehensive analysis of fenethylline’s health impacts, addiction potential, and dynamics of illicit trade. Initially developed for therapeutic use, fenethylline illicit production and use have escalated, raising concern about its physiological, psychological, and socio-economic impacts. This stimulant profoundly affects the central nervous system, enhancing wakefulness, concentration, and physical stamina while inducing euphoria. These effects come at the cost of serious adverse health outcomes, particularly with prolonged or heavy use, including cardiovascular complications, neurological damage, and addiction. The dependence-forming nature of captagon contributes to escalating substance use disorders, impacting healthcare systems. Beyond its biomedical implications, fenethylline trafficking has become a global issue, with supply chains deeply intertwined with politically unstable regions where illicit economies thrive. The geopolitical dimensions of captagon’s trade amplify its global security threat, influencing international relations and regional stability. This paper underscores the urgent need for systematic data collection and coordinated efforts to regulate illicit fenethylline production and distribution. Strategies such as improved surveillance, public health interventions, and international cooperation are essential to mitigate its escalating risks. Addressing this issue requires a multidisciplinary approach, integrating public health, law enforcement, and policy development to curb its impact on global health and security.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100323"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Receipt of medication for opioid use disorder among rural and urban veterans health administration patients” [Drug Alcohol Depend. Rep. 14 (2025) 100311]","authors":"Olivia C. Reynolds ,&nbsp;Kathleen F. Carlson ,&nbsp;Adam J. Gordon ,&nbsp;Robert L. Handley ,&nbsp;Benjamin J. Morasco ,&nbsp;Todd P. Korthuis ,&nbsp;Travis I. Lovejoy ,&nbsp;Jessica J. Wyse","doi":"10.1016/j.dadr.2025.100319","DOIUrl":"10.1016/j.dadr.2025.100319","url":null,"abstract":"","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"14 ","pages":"Article 100319"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}